Kansai Medical University is a private university in Moriguchi, Osaka, Japan. The predecessor of the school was founded in 1928, and it was chartered as a women's medical college in 1947. In 1954 it became coeducational.

During the past decade, Kansai Medical University conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Kansai Medical University" #1 sponsor was "Wakayama Medical University" with 3 trials, followed by "University Hospital Inselspital, Berne" with 2 trials sponsored, "Kansai Hepatobiliary Oncology Group" with 1 trials sponsored, "Kansai Medical University" with 1 trials sponsored and "Kyorin University" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Kansai Medical University" #1 collaborator was "Japan Clinical Oncology Group" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Kansai Medical University" are "Pancreatic Ductal Adenocarcinoma" (2 trials), "Biliary Tract Cancer" (1 trials), "Coronary Stenosis" (1 trials), "Glioblastoma" (1 trials) and "Hyperprolactinemia" (1 trials). Many other conditions were trialed in "Kansai Medical University" in a lesser frequency.

Most popular intervention types in "Kansai Medical University" are "Drug" (5 trials), "Diagnostic Test" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Bevacizumab" (1 trials), "Early treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®)" (1 trials), "FIRINOX" (1 trials), "Gemcitabine, S-1" (1 trials) and "Late treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Kansai Medical University" are 8 trials for "All" genders.

Currently, there are NaN active trials in "Kansai Medical University". undefined are not yet recruiting, 2 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Kansai Medical University, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Kansai Medical University, 2 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".